100.00% -40.50

Handel nachbörslich: 41.95 41.95 +

Citius Oncology Inc (TENK)

Citius Oncology Inc Aktie (TENK) Neueste Nachrichten

Citius Oncology Inc (TENK)

Citius Oncology Inc Aktie (TENK) Neueste Nachrichten

Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada

Civitas Resources started as Buy at J.P. Morgan ahead of likely strong buybacks - Seeking Alpha

Cytek Biosciences (NASDAQ:CTKB) Shares Down 2.6% - Defense World

CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle

Citius Pharmaceuticals Inc (CTXR)’s Day in Review: Closing at 0.50, Down by -2.90 - The Dwinnex

The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News

Results from Cytek BioSciences Inc (CTKB) show potential - US Post News

Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News

M&A News: Citigroup (NYSE:C) Sells Trust Business to JTC for $80M - TipRanks

Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Telix's Phase 3 ZIRCON Trial Published in Lancet Oncology - Mirage News

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News

Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex

CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com

Citius Oncology Inc. (CTOR) requires closer examination - US Post News

Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks

CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia

Citius Oncology Inc. completes strategic acquisition - Investing.com

Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com UK

Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ

Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex

CTOR stock touches 52-week low at $3.20 amid market fluctuations - Investing.com

TenX Keane Acquisition (NASDAQ:TENKR) Sees Significant Growth in Short Interest - Defense World

Citius merges oncology subsidiary with TenX Keane - Yahoo Finance

Citius merges oncology subsidiary with TenX Keane - Pharmaceutical Technology

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz

TenX Keane Acquisition (NASDAQ:TENK) Short Interest Update - MarketBeat

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - Kilgore News Herald

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Kilgore News Herald

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com

TenX Keane Acquisition Addresses Trading Halt, Continues - GlobeNewswire

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - StockTitan

TenX Keane addresses trading halt, continues toward combination closing - TipRanks

New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online

US FDA approves Citius' therapy for rare blood cancer - Reuters.com

Citius Pharmaceuticals stock falls despite approval of its lymphoma drug - Kursiv Media

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire

Biotech Alert: Searches spiking for these stocks today - TipRanks

Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz

(TENK) Trading Advice - news.stocktradersdaily.com

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq

TenX Keane Acquisition (TENK) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Lymphoma drug developer Citius Pharma finalizing spin-off of oncology division - Kursiv Media

Ähnlich wie TENK